Methods for genetic modification of megakaryocytes and platelets.

Methods for genetic modification of megakaryocytes and platelets. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Methods for genetic modification of megakaryocytes and platelets. Abstract Text:

Caroline Pendaries,Stephen P Watson,Jennifer C Spalton,

During recent decades there have been major advances in the fields of thrombosis and haemostasis, in part through development of powerful molecular and genetic technologies. Nevertheless, genetic modification of megakaryocytes and generation of mutant platelets in vitro remains a highly specialized area of research. Developments are hampered by the low frequency of megakaryocytes and their progenitors, a poor efficiency of transfection and a lack of understanding with regard to the mechanism by which megakaryocytes release platelets. Current methods used in the generation of genetically modified megakaryocytes and platelets include mutant mouse models, cell line studies and use of viruses to transform primary megakaryocytes or haematopoietic precursor cells. This review summarizes the advantages, limitations and technical challenges of such methods, with a particular focus on recent successes and advances in this rapidly progressing field including the potential for use in gene therapy for treatment of patients with platelet disorders.

Methods for genetic modification of megakaryocytes and platelets. Publishing Authors By Initials

C Pendaries,SP Watson,JC Spalton,

For similar biological phenomena, cell phenomena, and immunity: cell physiology: cell differentiation: hematopoiesis: thrombopoiesis research abstracts see: biological phenomena, cell phenomena, and immunity: cell physiology: cell differentiation: hematopoiesis: thrombopoiesis research

PUBMED ID PMID:

MEDLINE DATE:

Methods for genetic modification of megakaryocytes and platelets. Journal Published:

PUBLICATION TYPE: Review

Journal: Platelets

VOLUME: 18

Page Numbers: 393-408

Journal Abbreviation: Platelets

ISSN: 0953-7104

DAY: 30

MONTH: Sep

YEAR: 2007

Methods for genetic modification of megakaryocytes and platelets. Information

Number of References: 102

LANGUAGE: eng

NlmUniqueID: 9208117

Methods for genetic modification of megakaryocytes and platelets. Keywords Mesh Terms:

KEYWORDS: Thrombopoiesis

MESH TERMS: metabolism

Chemical & Substance for Abstract: Methods for genetic modification of megakaryocytes and platelets. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Methods for genetic modification of megakaryocytes and platelets.

AFFILIATION: Centre for Cardiovascular Sciences, Institute for Biomedical Research, Wolfson Drive, The Medical School, University of Birmingham, Edgbaston, Birmingham, UK.

Country: England

AGENCY: United Kingdom Wellcome T

GRANT:

ACRONYM:

MEDLINETA: Platelets

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Methods for genetic modification of megakaryocytes and platelets Related Publications

• Candida endophthalmitis in a heroin addict: a case report.
• Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients.
• Changes in anterior chamber flare and cells following cataract surgery.
• Continued breakdown of the blood aqueous barrier following cataract surgery.
• Diagnosis and management of an occult cyclodialysis cleft.
• Horner's syndrome: an electron microscopic study of a human iris.
• Laser flare intensity in diabetics.
• Lyme disease.
• Measurement of flare.
• Methods for genetic modification of megakaryocytes and platelets.
• Progress in uveitis.
• Ptosis caused by pachydermoperiostosis.
• Sarcoidosis with infiltration of the external ocular muscles.
• Surgical corneal clouding.
• The effects of subconjunctival betamethasone on the blood aqueous barrier following cataract surgery: a double-blind randomised prospective study.
• The formulation of nasal preparations.
• Treatment of senile entropion with botulinum toxin.
• Use of soft contact lenses in an eye casualty department for the primary treatment of traumatic corneal abrasions.